Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL835328 | 0.84 | — | — | |
| SCHEMBL8465036 | 0.79 | DNM1 (0.38) | DNM1ALDH1A1TDP1TSHRSMN1; SMN2 | |
| SCHEMBL8310868 | 0.77 | DNM1 (0.36) | DNM1ALDH1A1TDP1TSHRSMN1; SMN2 | |
| SCHEMBL832921 | 0.75 | DNM1 (0.35) | DNM1ALDH1A1TDP1TSHRSMN1; SMN2 | |
| SCHEMBL9528056 | 0.75 | DNM1 (0.35) | DNM1ALDH1A1TDP1TSHRSMN1; SMN2 | |
| SCHEMBL2270760 | 0.75 | FDPS (0.36) | DNM1ALDH1A1TDP1TSHRSMN1; SMN2 | |
| SCHEMBL16969581 | 0.75 | FDPS (0.36) | DNM1ALDH1A1TDP1TSHRSMN1; SMN2 | |
| SCHEMBL7088918 | 0.75 | DNM1 (0.35) | DNM1ALDH1A1TDP1TSHRSMN1; SMN2 | |
| SCHEMBL2229881 | 0.75 | DNM1 (0.35) | DNM1ALDH1A1TDP1TSHRSMN1; SMN2 | |
| SCHEMBL27574896 | 0.75 | DNM1 (0.35) | DNM1ALDH1A1TDP1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1908466-B1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2014-02-19 | — | — | EP | disclosed |
| US-8497397-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| EP-1880720-B1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2013-02-13 | — | — | EP | disclosed |
| US-8344029-B2 | Substituted propanamide derivative and pharmaceutical composition containing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20120220593-A1 | Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-8143446-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20090292024-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAIICHI SANKYO COMPANY , LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1908466-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-04-09 | — | — | EP | disclosed |
| EP-1880720-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292024-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | PTMS, C1S, ACP3 | DNM1 3763/4885ALDH1A1 298/4885TDP1 3856/4885 |
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACR, NAT1, C1S | DNM1 4848/4885ALDH1A1 75/4885TDP1 1470/4885 |
| US-20120220593-A1 | Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same | ACR, NAT1, C1S | DNM1 4848/4885ALDH1A1 75/4885TDP1 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.